rTMS for Neuroenhancement

Inclusion Criteria: * Male or female, 22 to 70 years of age * Freely provides written informed consent * In good general health, as ascertained by medical history * If female, not breastfeeding, no known or suspected pregnancy, a status of non- childbearing potential or use of an acceptable form of birth control * If subject is in menopausal transition, the subject must be stabilized on hormonal treatment. * Subject scored a 2 or higher on PHQ-9 sleep related question (#3), OR subject scored 2 or more on at least 2 QIDS-SR sleep related questions (#'s 1-4) * If subject is on any psychiatric or sleep medication, dose must be stable for two weeks prior to enrollment and remain stable throughout the trial. Exclusion Criteria: * Subject satisfies any one or more of the contraindications for TMS Therapy per current treatment guidelines as determined by the PI. * History of head trauma associated with loss of consciousness or diagnosed as concussion. * History of fainting, syncope, hearing problems or ringing in the ears (tinnitus) * Has any metallic implant(s) in or near the head (e.g., pacemaker, defibrillator, neurostimulator, etc.) including any splinters, fragments, clips, etc. * Has an implanted stimulator device (including device leads) in or near the head. (e.g. deep brain stimulator, cochlear implant, vagus nerve stimulator.) * Has medication infusion device. * Subjects with any prior TMS or MRI complications which, in the opinion of the investigator, might interfere with safety, study participation, or which might confound data interpretation, * Current diagnosis of a Substance Use Disorder (Abuse or Dependence, as defined by DSM-IV-TR), with the exception of nicotine dependence. * Current diagnosis or known history of neurologic or neuropsychiatric disease (e.g., epilepsy, convulsion, seizure) * Has a clinically significant abnormality on the screening examination that might affect safety, study participation, or confound interpretation of study results. * Participation in any clinical trial with an investigational drug or device within the past month or concurrent with study participation.